Podlipská, Jana
Guermazi, Ali
Lehenkari, Petri
Niinimäki, Jaakko
Roemer, Frank W.
Arokoski, Jari P.
Kaukinen, Päivi
Liukkonen, Esa
Lammentausta, Eveliina
Nieminen, Miika T.
Tervonen, Osmo
Koski, Juhani M.
Saarakkala, Simo
Article History
Received: 3 December 2015
Accepted: 12 February 2016
First Online: 1 March 2016
Change Date: 16 September 2016
Change Type: Update
Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Competing interests
: J.P., P.L., J.N., P.K., E.L., M.T.N., O.T., S.S., declares no competing financial interests. A.G. reports activities not related to the present article: received personal fees from MerckSerono, Genzyme, TissueGene, AstraZeneca, and Orthotrophix; is a shareholder in Boston Imaging Core Lab. (BICL), LLC, a company providing image assessment services to academia and the pharmaceutical industry. F.W.R. reports activities not related to the present article: is CMO and shareholder in Boston Imaging Core Lab. (BICL), LLC, a company providing image assessment services to academia and the pharmaceutical industry. J.P.A. reports activities not related to the present article: personal fees from MSD Finland Oy, personal fees from Pfizer Oy, personal fees from Mundipharma Oy, personal fees from Eli Lilly Finland Oy. J.M.K. reports activities not related to the present article: personal fees from Abbott, personal fees from AbbVie, personal fees from MSD, personal fees from Pfizer, personal fees from Roche, personal fees from Bristol-Myers Squibb, personal fees from Orion, personal fees from UCB, personal fees from GE.